The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

Eisai Company Limited (4523.T) has reported a modest revenue increase in its Q2 Fiscal 2024 earnings call, with significant developments in its Alzheimer's disease treatments. The pharmaceutical ...

Eisai Company Limited (4523.T) has reported a modest revenue increase in its Q2 Fiscal 2024 earnings call, with significant developments in its Alzheimer's disease treatments. The pharmaceutical giant ...

Eisai Company Limited (ESALY (OTC:ESAIY)) has reported a modest revenue growth of 3% year-on-year in its Q2 Fiscal 2024 earnings call, totaling JPY 385 billion. The pharmaceutical segment saw a 5% ...

Eisai Company Limited (ESALY (OTC:ESAIY)) has reported a modest revenue growth of 3% year-on-year in its Q2 Fiscal 2024 earnings call, totaling JPY 385 billion. The pharmaceutical segment saw a 5% ...

Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

Eisai has retreated from the optimistic view ... That has prompted the company to reduce its fiscal 2024/25 projections for the drug to JPY 42.5 billion ($279 million) from JPY 56.5 billion ...